Literature DB >> 6313026

Analgesic interaction between nitrous oxide and delta-9-tetrahydrocannabinol in the rat.

G P Novelli, V A Peduto, E Bertol, F Mari, E Pieraccioli.   

Abstract

The analgesic activities of a 75:25% nitrous oxide-oxygen mixture administered for 15 min, of delta-9-tetrahydrocannabinol (THC) 10 mg kg-1 i.p., and of a combination of both, were evaluated in the rat by tail-flick and hot-plate tests. The nitrous oxide-oxygen mixture produced a significant increase in the pain threshold. The analgesic activity of THC was similar in extent but of longer duration than that of nitrous oxide. The cannabinoid also induced some locomotor and behavioural modifications. When both THC and the nitrous oxide-oxygen mixture were administered, a significant potentiation of the analgesic response was produced, without modification of the locomotor and behavioural responses that were induced by THC alone. Such mixtures may prove of value in the control of chronic pain in man.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313026     DOI: 10.1093/bja/55.10.997

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  3 in total

1.  Inhaled delivery of Δ(9)-tetrahydrocannabinol (THC) to rats by e-cigarette vapor technology.

Authors:  Jacques D Nguyen; Shawn M Aarde; Sophia A Vandewater; Yanabel Grant; David G Stouffer; Loren H Parsons; Maury Cole; Michael A Taffe
Journal:  Neuropharmacology       Date:  2016-05-30       Impact factor: 5.250

2.  Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain.

Authors:  Erin M Rock; Cheryl L Limebeer; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2018-09-17       Impact factor: 4.530

Review 3.  Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system.

Authors:  John M McPartland; Geoffrey W Guy; Vincenzo Di Marzo
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.